Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ncctg n9831 (14) 14
index medicus (11) 11
oncology (10) 10
female (9) 9
humans (9) 9
breast cancer (8) 8
trastuzumab (7) 7
follow-up (6) 6
immunohistochemistry (6) 6
joint analysis (6) 6
adult (5) 5
breast neoplasms - drug therapy (5) 5
breast neoplasms - genetics (5) 5
breast neoplasms - pathology (5) 5
plus adjuvant chemotherapy (5) 5
receptor, erbb-2 - analysis (5) 5
cardiotoxicity (4) 4
care and treatment (4) 4
chemotherapy (4) 4
middle aged (4) 4
nsabp b-31 (4) 4
pathology (4) 4
research (4) 4
therapy (4) 4
abridged index medicus (3) 3
breast neoplasms - chemistry (3) 3
chemotherapy, adjuvant (3) 3
neoplasm staging (3) 3
neoplasms (3) 3
receptor, erbb-2 - genetics (3) 3
receptor, erbb-2 - metabolism (3) 3
skin and connective tissue diseases (3) 3
adjuvant chemotherapy (2) 2
aged (2) 2
algorithms (2) 2
american society (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
biomarkers, tumor - analysis (2) 2
biomarkers, tumor - genetics (2) 2
breast neoplasms - diagnosis (2) 2
breast neoplasms - mortality (2) 2
cancer (2) 2
cardiac dysfunction (2) 2
clinical-practice (2) 2
diagnosis (2) 2
disease-free survival (2) 2
erbb-2 protein (2) 2
estrogen (2) 2
false negative reactions (2) 2
heart-failure (2) 2
her2 (2) 2
her2 testing (2) 2
immunohistochemistry - methods (2) 2
in situ hybridization, fluorescence - methods (2) 2
kaplan-meier estimate (2) 2
medicine & public health (2) 2
monoclonal-antibody (2) 2
patients (2) 2
practice guidelines (2) 2
practice guidelines as topic (2) 2
proportional hazards models (2) 2
randomized-trial (2) 2
retrospective studies (2) 2
safety (2) 2
survival (2) 2
trastuzumab - adverse effects (2) 2
trial comparing doxorubicin (2) 2
united states (2) 2
usage (2) 2
2-positive breast-cancer (1) 1
3122 cancers (1) 1
adjuvant (1) 1
adjuvant therapy (1) 1
adjuvant trastuzumab (1) 1
adjuvant treatment (1) 1
administration, oral (1) 1
ago recommendations (1) 1
american-society (1) 1
amplification (1) 1
analysis (1) 1
antibodies, monoclonal, humanized (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
benefit (1) 1
biomarkers, tumor - metabolism (1) 1
biotechnology (1) 1
breast neoplasms (1) 1
breast neoplasms - economics (1) 1
breast neoplasms - immunology (1) 1
breast neoplasms - metabolism (1) 1
breast neoplasms - surgery (1) 1
breast-cancer (1) 1
cancer and oncology (1) 1
cancer och onkologi (1) 1
cancer therapies (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial
by Perez, Edith A and Thompson, E. Aubrey and Ballman, Karla V and Anderson, S. Keith and Asmann, Yan W and Kalari, Krishna R and Eckel-Passow, Jeanette E and Dueck, Amylou C and Tenner, Kathleen S and Jen, Jin and Fan, Jian-Bing and Geiger, Xochiquetzal J and McCullough, Ann E and Chen, Beiyun and Jenkins, Robert B and Sledge, George W and Winer, Eric P and Gralow, Julie R and Reinholz, Monica M
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 7, pp. 701 - 708
Purpose To develop a genomic signature that predicts benefit from trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. Patients and... 
TUMOR-INFILTRATING LYMPHOCYTES | NCCTG N9831 | BENEFIT | ONCOLOGY | 2-POSITIVE BREAST-CANCER | JOINT ANALYSIS | EXPRESSION | CHEMOTHERAPY | Biomarkers, Tumor - analysis | Breast Neoplasms - immunology | Genomics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Kaplan-Meier Estimate | Proportional Hazards Models | Transcriptome | Disease-Free Survival | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | DNA, Neoplasm - analysis | Chemotherapy, Adjuvant | Receptor, ErbB-2 - analysis | Molecular Targeted Therapy - methods | Trastuzumab | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
by Martin, Miguel and Holmes, Frankie A and Ejlertsen, Bent and Delaloge, Suzette and Moy, Beverly and Iwata, Hiroji and von Minckwitz, Gunter and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Tomašević, Zorica and Denduluri, Neelima and Šeparović, Robert and Gokmen, Erhan and Bashford, Anna and Ruiz Borrego, Manuel and Kim, Sung-Bae and Kim, Seung Jin and Jakobsen, Erik Hugger and Ciceniene, Audrone and Inoue, Kenichi and Overkamp, Friedrich and Heijns, Joan B and Armstrong, Anne C and Link, John S and Joy, Anil Abraham and Bryce, Richard and Wong, Alvin and Moran, Susan and Yao, Bin and Xu, Feng and Xu, Binghe and Auerbach, Alan and Buyse, Marc and Chan, Arlene and Harvey, Vernon and Tomek, Rudolf and Robert, Nicholas J and Gore, Ira and Smith, John W and Smith, Julie C and Masuda, Norikazu and Di Sean Kendall, S and Harker, William Graydon and Petrakova, Katarina and Guerrero Zotano, Angel and Simon, Amparo Ruiz and Konstantinovic, Zora Neskovic and Iannotti, Nicholas O and Tassone, Pierfrancesco and Rodriguez, Gladys I and Jáñez Martinez, Noelia and Crespo Massieu, Carmen and Smickoska, Snezana and Somali, Isil and Yilmaz, Ugur and Alonso, Mirta Garcia and Rosales, Adolfo Murias and Cold, Soeren and Knoop, Ann Soegaard and Patt, Debra and Hellerstedt, Beth A and Morales Murillo, Serafin and Mayer, Ingrid A and Means-Powell, Julie Ann and Hui, Rina and Senecal, Francis M and De Boer, Richard Hendry and Shen, Zhenzhou and Luczak, Adam Andrzej and Chui, Joanna W.Y and Chui, Stephen and Tsang, Janice Wing-hang and Lang, Istvan and Rai, Yoshiaki and Hozumi, Yasuo and Ten Tije, Albert J and Bhandari, Manish and Osborne, Cynthia R.C and Ohtani, Shoichiro and Higaki, Kenji and Watanabe, Junichiro and Watanabe, Kenichi and Taguchi, Tetsuya and Taguchi, Kazunori and Takahashi, Masato and Filipovic, Sladjana and Hansen, Vincent L and Rao, Vijayarama Phooshkooru and Gupta, Manish and Petrov, Petar and Coudert, Bruno and Vojnovic, Zeljko and Polya, Zsofia and Miyaki, Toshiko and Yamamoto, Naohito and Brincat, Stephen and Lesniewski-Kmak, Krzysztof and Chmielowska, Ewa and ... and ExteNET Study Grp and ExteNET Study Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1688 - 1700
ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after... 
LAPATINIB | NCCTG N9831 | NSABP B-31 | HERA TRIAL | MULTICENTER | ONCOLOGY | TYROSINE KINASE | FOLLOW-UP | JOINT ANALYSIS | ESTROGEN-RECEPTOR | CHEMOTHERAPY | Breast Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Mastectomy - methods | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Time Factors | Neoplasm Invasiveness - pathology | Adult | Female | Chemotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Administration, Oral | Japan | Kaplan-Meier Estimate | Proportional Hazards Models | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Neoplasm Staging | Quinolines - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Risk-imaging mismatch: Why is there a disconnect?
by Dang, Chau T and Yu, Anthony F and Liu, Jennifer and Steingart, Richard
Journal of Clinical Oncology, ISSN 0732-183X, 10/2018, Volume 36, Issue 30, pp. 2975 - 2977
VENTRICULAR EJECTION FRACTION | ADJUVANT CHEMOTHERAPY | NCCTG N9831 | PRACTICE GUIDELINES | ONCOLOGY | HEART-FAILURE | RANDOMIZED-TRIAL | FOLLOW-UP | CARDIAC DYSFUNCTION | EARLY BREAST-CANCER | AMERICAN SOCIETY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Change in pattern of HER2 fluorescent in situ hybridization (FISH) results in breast cancers submitted for FISH testing: Experience of a reference laboratory using US Food and Drug Administration criteria and American Society of Clinical Oncology and College of American Pathologists guidelines
by Shah, Mithun Vinod and Wiktor, Anne E and Meyer, Reid G and Tenner, Kathleen S and Ballman, Karla V and Green, Stefan J and Sukov, William R and Ketterling, Rhett P and Perez, Edith A and Jenkins, Robert B
Journal of Clinical Oncology, ISSN 0732-183X, 10/2016, Volume 34, Issue 29, pp. 3502 - 3510
PurposeIn 1998, the US Food and Drug Administration (FDA) approved human epidermal growth factor receptor 2 (HER2) testing guidelines to determine eligibility... 
NCCTG N9831 | NSABP B-31 | TRASTUZUMAB | EFFICACY | ONCOLOGY | RECOMMENDATIONS | SAFETY | CARDIOTOXICITY | MONOCLONAL-ANTIBODY | PLUS ADJUVANT CHEMOTHERAPY | JOINT ANALYSIS | Immunohistochemistry | Receptor, ErbB-2 - genetics | United States | Humans | False Negative Reactions | False Positive Reactions | Breast Neoplasms - drug therapy | Nucleic Acid Amplification Techniques | Medical Oncology | Pathology | Breast Neoplasms - chemistry | Breast Neoplasms - genetics | Societies, Medical | Female | Receptor, ErbB-2 - analysis | In Situ Hybridization, Fluorescence - methods | United States Food and Drug Administration | Practice Guidelines as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low?
by Dang, Chau T and Blaes, Anne and Lynce, Filipa and Swain, Sandra M and Dent, Susan
JACC: Cardiovascular Imaging, ISSN 1936-878X, 08/2018, Volume 11, Issue 8, pp. 1094 - 1097
trastuzumab | breast cancer | cardiotoxicity | NSABP B-31 | NCCTG N9831 | CARDIAC & CARDIOVASCULAR SYSTEMS | HEART-FAILURE | RANDOMIZED-TRIAL | CARDIAC DYSFUNCTION | FOLLOW-UP | HER2-POSITIVE BREAST-CANCER | TRIAL COMPARING DOXORUBICIN | OLDER PATIENTS | PLUS ADJUVANT CHEMOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence in Situ Hybridization for Breast Cancer
by Lim, Tse Hui and Lim, Alvin Soon Tiong and Thike, Aye Aye and Tien, Sim Leng and Tan, Puay Hoon
Archives of Pathology and Laboratory Medicine, ISSN 0003-9985, 02/2016, Volume 140, Issue 2, pp. 140 - 147
Context.-Human epidermal growth factor receptor 2 (HER2/neu) amplification is used as a predictive marker for trastuzumab treatment in breast cancer. Both... 
ADJUVANT CHEMOTHERAPY | MEDICINE, RESEARCH & EXPERIMENTAL | NCCTG N9831 | INTRATUMORAL HETEROGENEITY | POLYSOMY 17 | MONOCLONAL-ANTIBODY | PATHOLOGY | INVASIVE MAMMARY CARCINOMAS | MESSENGER-RNA | FORMALIN FIXATION | PROTEIN EXPRESSION | HER2 STATUS | MEDICAL LABORATORY TECHNOLOGY | Reproducibility of Results | Receptor, ErbB-2 - genetics | Biomarkers, Tumor - analysis | Humans | Genetic Testing - methods | Immunohistochemistry - methods | Breast Neoplasms - genetics | Female | Biomarkers, Tumor - genetics | Retrospective Studies | Receptor, ErbB-2 - analysis | In Situ Hybridization, Fluorescence - methods | Practice Guidelines as Topic | Immunohistochemistry | Care and treatment | Epidermal growth factor | Algorithms | Medical societies | Fluorescence | Practice guidelines (Medicine) | Genetic aspects | Breast cancer | Genetic screening | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study
by Lidbrink, Elisabet and Chmielowska, E and Otremba, B and Bouhlel, A and Lauer, S and Liste Hermoso, M and Nüesch, E and Shing, M and Misra, V
Breast Cancer Research and Treatment, ISSN 0167-6806, 2/2019, Volume 174, Issue 1, pp. 187 - 196
Cardiac dysfunction risk associated with intravenous trastuzumab (H IV) treatment may differ in real-world practice versus randomized trials. We investigated... 
Real-world population | Medicine & Public Health | Cardiac adverse events | HER2-positive early breast cancer | HER2-targeted therapies | Oncology | Trastuzumab | NCCTG N9831 | FOLLOW-UP | CARDIOTOXICITY | HERA | PACLITAXEL | TRIAL COMPARING DOXORUBICIN | THERAPY | ONCOLOGY | SAFETY ANALYSIS | PLUS ADJUVANT CHEMOTHERAPY | Heart failure | Heart | Care and treatment | Relapse | Oncology, Experimental | Adjuvant treatment | Breast cancer | Research | Risk factors | Diseases | Cardiac patients | Carboplatin | Cancer | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study
by McCullough, Ann E and Dell’Orto, Patrizia and Reinholz, Monica M and Gelber, Richard D and Dueck, Amylou C and Russo, Leila and Jenkins, Robert B and Andrighetto, Stefania and Chen, Beiyun and Jackisch, Christian and Untch, Michael and Perez, Edith A and Piccart-Gebhart, Martine J and Viale, Giuseppe
Breast Cancer Research and Treatment, ISSN 0167-6806, 2/2014, Volume 143, Issue 3, pp. 485 - 492
Choice of therapy for breast cancer relies on human epidermal growth factor receptor-2 (HER2) and estrogen receptor α (ER) status. Before randomization in the... 
Local versus central laboratory concordance | Medicine & Public Health | Central laboratory review | HER2 testing | Oncology | Breast cancer | Estrogen receptor testing | NCCTG N9831 | PROGESTERONE-RECEPTORS | ADJUVANT THERAPY | CLINICAL-ONCOLOGY/COLLEGE | ONCOLOGY | ESTROGEN | GUIDELINE RECOMMENDATIONS | AMERICAN-SOCIETY | Immunohistochemistry | Receptor, ErbB-2 - genetics | Early Detection of Cancer | Humans | Receptor, ErbB-2 - metabolism | In Situ Hybridization, Fluorescence | Breast Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms - genetics | Estrogen Receptor alpha - genetics | Breast Neoplasms - pathology | Estrogen Receptor alpha - metabolism | Female | Italy | Quinazolines - administration & dosage | Biomarkers, Tumor - genetics | Trastuzumab | Care and treatment | Medical laboratories | Health aspects | Estrogen | estrogen receptor testing | breast cancer | central laboratory review | local versus central laboratory concordance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text ERBB2 (HER2) Testing in Breast Cancer
by Hilal, Talal and Romond, Edward H
JAMA, ISSN 0098-7484, 03/2016, Volume 315, Issue 12, pp. 1280 - 1281
ERBB2 (HER2) (the second human epidermal growth factor receptor discovered) is one of the most important tumor parameters to be evaluated for any patient... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | NCCTG N9831 | Carcinoma, Ductal, Breast - genetics | Breast Neoplasms - chemistry | Breast Neoplasms - genetics | Genes, erbB-2 | Humans | Adult | Female | Breast Neoplasms - diagnosis | Carcinoma, Ductal, Breast - chemistry | Carcinoma, Ductal, Breast - diagnosis | Immunohistochemistry | Care and treatment | Usage | Analysis | Breast cancer | Mammography | Diagnosis | Medical screening | Medical prognosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium
by Seferina, S.C and Boer, M. de and Derksen, M.W.J and Berkmortel, F. van den and Kampen, R.J. van and Wouw, A.J. van de and Joore, M and Peer, P.G.M and Voogd, A.C and Tjan-Heijnen, V.C
Oncologist, ISSN 1083-7159, 2016, Volume 21, Issue 5, pp. 555 - 562
INTRODUCTION: We assessed the incidence and timing of first cardiac events, impact on trastuzumab prescription, and role of left ventricular ejection fraction... 
Adjuvant trastuzumab | Cardiotoxicity | Cardiac monitoring | Daily practice | NSABP B-31 | NCCTG N9831 | CARDIOMYOPATHY | DOXORUBICIN | FOLLOW-UP | JOINT ANALYSIS | CHEMOTHERAPY | TRIAL | ONCOLOGY | ERBB2 | CLINICAL-PRACTICE | Humans | Middle Aged | Ventricular Function, Left - drug effects | Cardiotoxicity - epidemiology | Trastuzumab - adverse effects | Breast Neoplasms - drug therapy | Incidence | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Adult | Breast Neoplasms - mortality | Female | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Receptor, ErbB-2 - analysis | Neoplasm Staging | Breast Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status
by Garrison, Louis P and Lalla, Deepa and Brammer, Melissa and Babigumira, Joseph B and Wang, Bruce and Perez, Edith A
Cancer, ISSN 0008-543X, 09/2013, Volume 119, Issue 17, pp. 3113 - 3122
Both immunohistochemistry and fluorescence in situ hybridization analyses of HER2 in breast cancer yield similar rates of concordance (92%) among expert... 
trastuzumab | Herceptin | early breast cancer | economics | adjuvant | HER2 testing | cost‐effectiveness | cost‐utility | pharmacoeconomics | HER2 | cost-effectiveness | cost-utility | SURVIVAL | NCCTG N9831 | STATISTICS | RECEPTOR | AMPLIFICATION | THERAPY | ONCOLOGY | PLUS ADJUVANT CHEMOTHERAPY | PATHOLOGISTS GUIDELINE RECOMMENDATIONS | IMMUNOHISTOCHEMISTRY | Breast Neoplasms - economics | United States | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Breast Neoplasms - metabolism | Sensitivity and Specificity | Biomarkers, Tumor - metabolism | Adult | Female | Immunohistochemistry - economics | Quality-Adjusted Life Years | Antibodies, Monoclonal, Humanized - therapeutic use | In Situ Hybridization, Fluorescence - economics | Decision Support Techniques | False Negative Reactions | Breast Neoplasms - drug therapy | Health Care Costs | Algorithms | Patient Acceptance of Health Care | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Cost-Benefit Analysis | Aged | Neoplasm Staging | Trastuzumab | Usage | Diagnostic immunohistochemistry | Fluorescence in situ hybridization | Reports | Breast cancer | Diagnosis | Research | Medical care, Cost of
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
by Schramm, Amelie and De Gregorio, Nikolaus and Widschwendter, Peter and Fink, Visnja and Huober, Jens
Breast Care, ISSN 1661-3791, 07/2015, Volume 10, Issue 3, pp. 173 - 178
About 20% of all breast cancer patients have a human epidermal growth factor receptor 2 (HER2)-positive breast tumor. This entity underwent an impressive... 
Review Article | Targeted therapies | Dual HER2 blockade | HER2-positive breast cancer | NCCTG N9831 | OPEN-LABEL | KINASE INHIBITOR | AGO RECOMMENDATIONS | JOINT ANALYSIS | TRASTUZUMAB EMTANSINE | OBSTETRICS & GYNECOLOGY | ONCOLOGY | PHASE-3 TRIAL | PLUS ADJUVANT CHEMOTHERAPY | CLINICAL-PRACTICE | AMERICAN SOCIETY | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Inter-observer agreement in reporting HER 2 Neu protein over expression by immunohistochemistry
by Al Haddabi, Ibrahim and Qureshi, Asim and Saparamadu, Anna and Al Hamdani, Aisha and Al Riyami, Marwa and Ganguly, Shyam
Indian Journal of Pathology and Microbiology, ISSN 0377-4929, 2014, Volume 57, Issue 2, pp. 201 - 204
Introduction: HER 2 Neu protein overexpression and its detection by immunohistochemistry (IHC) has become quiet critical because of its relevance in regards to... 
peer review | immunohistochemistry | HER 2 Neu | NCCTG N9831 | HERCEPTEST | PATHOLOGY | REPRODUCIBILITY | CHEMOTHERAPY | BREAST-CANCER | OVEREXPRESSION | THERAPY | HER2 | CARCINOMA | Gene Expression | Tertiary Care Centers | Humans | Health Services Research | Immunohistochemistry - standards | Immunohistochemistry - methods | Pathology - standards | Breast Neoplasms - pathology | Female | Breast Neoplasms - diagnosis | Retrospective Studies | Pathology - methods | Receptor, ErbB-2 - analysis | Observer Variation | Immunohistochemistry | Medicine, Experimental | Medical research | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: The SOLD randomized clinical trial
by Joensuu, Heikki and Fraser, Judith and Wildiers, Hans and Huovinen, Riikka and Auvinen, Päivi and Utriainen, Meri and Nyandoto, Paul and Villman, Kenneth K and Halonen, Päivi and Granstam-Björneklett, Helena and Lundgren, Lotta and Sailas, Liisa and Turpeenniemi-Hujanen, Taina and Tanner, Minna and Yachnin, Jeffrey and Ritchie, Diana and Johansson, Oskar and Huttunen, Teppo and Neven, Patrick and Canney, Peter and Harvey, Vernon J and Kellokumpu-Lehtinen, Pirkko-Liisa and Lindman, Henrik and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Institutionen för immunologi, genetik och patologi and Uppsala universitet and Experimentell och klinisk onkologi
JAMA Oncology, ISSN 2374-2437, 09/2018, Volume 4, Issue 9, pp. 1199 - 1206
IMPORTANCE Trastuzumab plus chemotherapy is the standard adjuvant treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive early... 
NCCTG N9831 | THERAPY | ONCOLOGY | SAFETY | FOLLOW-UP | COMBINATION | JOINT ANALYSIS | DOCETAXEL | Online First | Original Investigation | Research | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.